3 Promising Growth Stocks You Can Buy for Less Than $100

The article identifies Carnival, AstraZeneca, and Block as potentially undervalued growth stocks. Carnival's revenue increased 7% year-over-year to $5.8 billion, but its debt load remains substantial at $25.5 billion. AstraZeneca projects sales to top $80 billion by 2030, with oncology products driving growth. Block's revenue is down 3% YTD amid economic challenges, however revenue grew 37% in 3 years, with potential upside from its Cash App and merchant payment solutions.

Analysis

The article identifies Carnival (CCL), AstraZeneca (AZN), and Block (SQ) as potentially undervalued growth stocks suitable for a diversified investment approach. Carnival, trading near $23, reported a 7% year-over-year revenue increase to $5.8 billion in its most recent quarter and nearly doubled its operating income to $543 million, demonstrating robust demand in the cruise sector. However, its significant long-term debt of $25.5 billion remains a concern, as interest and debt repayment costs of $629 million led to a quarterly net loss, though the company is actively working on debt reduction and trades at an estimated 13 times forward earnings. AstraZeneca, priced under $70, is highlighted for its strong pharmaceutical growth, with oncology products alone generating over $5.6 billion in sales in the first three months of the year and a corporate projection for annual sales to exceed $80 billion by 2030, up from $54 billion recently. Its valuation appears attractive with a price/earnings-to-growth multiple below 1 and a 2.3% dividend yield. Block, trading near $60, offers exposure to digital payments and cryptocurrency trends, particularly through its Cash App and merchant services. Despite a recent 3% quarterly revenue decline and a stock price decrease of over 30% year-to-date amid economic challenges, Block achieved 37% revenue growth over the past three years, reaching $24.1 billion, and trades at less than 16 times estimated future earnings, below the S&P 500 average.

Key Decisions for Investors

• Investors should critically assess Carnival's (CCL) ability to manage its substantial debt burden against its strong operational recovery and appealing forward valuation, while also noting its absence from a specific analyst's top 10 buy list.
• AstraZeneca (AZN) warrants consideration for its growth outlook driven by a robust drug portfolio and ambitious sales targets, complemented by a sub-1 PEG ratio and a dividend yield, though inherent risks in pharmaceutical development persist.
• Block (SQ) could be viewed as a long-term growth opportunity leveraged to digital finance and cryptocurrency adoption, but investors must weigh its recent underperformance and market sensitivity against its historical growth and relatively low forward earnings multiple.
• Adopting the article's suggestion to diversify investments across several growth stocks can help mitigate company-specific risks, particularly when considering companies with varying stages of turnaround or dependence on volatile market segments.